Summary

The assumption that animal models are reasonably predictive of human outcomes provides the basis for their widespread use in toxicity testing and in biomedical research aimed at developing cures for human diseases. To investigate the validity of this assumption, the comprehensive 'Scopus' biomedical bibliographic databases were searched for published systematic reviews of the human clinical or toxicological utility of animal experiments. Of 20 reviews examining clinical utility, authors concluded that the animal models were substantially consistent with or useful in advancing clinical outcomes in only two cases, and the conclusion in one case was contentious. Included were reviews of the clinical utility of experiments expected by ethics committees to lead to medical advances, of highly-cited experiments published in major journals
Trends in laboratory animal use
Annually, many millions of animals are used worldwide in toxicity testing and biomedical research aimed at developing cures for human diseases. Steady increases in the use of genetically modified animals and several large scale chemical testing programs within the US and Europe are increasing laboratory animal use.
Claims supporting laboratory animal use
Biomedical research using laboratory animals is highly controversial. Advocates frequently claim such research is vital for preventing, curing or alleviating human diseases (e.g. Brom, 2002; Festing, 2004) , that the greatest achievements of medicine have been possible only due to the use of animals (e.g. Pawlik, 1998) , and that the complexity of humans requires nothing less than the complexity of laboratory animals to effectively model during biomedical investigations (e.g. Kjellmer, 2002) . They even claim that medical progress would be "severely maimed by prohibition or severe curtailing of animal experiments," and that "catastrophic consequences would ensue" (Osswald, 1992 ).
The necessity of systematic reviews
The premise that laboratory animal models are generally predictive of human outcomes is the basis for their widespread use in human toxicity testing, and in the safety and efficacy testing of putative chemotherapeutic agents and other clinical interventions. However, numerous cases of discordance between human and laboratory animal outcomes suggest that this premise may well be incorrect, and that the utility of animal experiments for these purposes may not be assured. On the other hand, only small numbers of experiments are normally reviewed in such case studies, and their selection may be subject to bias.
To provide more definitive conclusions, systematic reviews of the human clinical or toxicological utility of large numbers of animal experiments are necessary. Experiments included in such reviews are selected without bias, via randomisation or similarly methodical and impartial means. A growing number of such reviews and meta-analyses have been published, which collectively provide important insights into the human clinical and toxicological utility of animal models. Their identification and examination was the purpose of this review.
Methods
The 'Scopus' biomedical bibliographic databases -among the world's most comprehensive -were searched for systematic reviews of the human clinical or toxicological utility of animal experiments published in the peer-reviewed biomedical literature. To minimise bias, reviews were included only when systematically conducted using randomisation or similarly methodical and impartial means to select animal studies.
Only reviews examining the human toxicological predictivity or utility of animal experiments, their contributions towards the development of prophylactic, diagnostic or therapeutic interventions with clear potential for combating human diseases or injuries, or their consistency with human clinical outcomes, were examined. Reviews focusing only on the contributions of animal experiments towards increased understanding of the aetiological, pathogenesic or other aspects of human diseases, or on the clinical utility of animal experiments in non-human species, for example, were not included. 
Results
As of
Discussion
Space constraints preclude a detailed examination of these 27 reviews, which is provided elsewhere (Knight, 2007a) . However, three different approaches that sought to determine the maximum human clinical utility that may be achieved by animal experiments were of particular interest. Lindl and colleagues (2005; 2006) examined animal experiments conducted at three German universities between 1991 and 1993 that had been approved by animal ethics committees at least partly on the basis of claims by researchers that the experiments might lead to concrete advances towards the cure of human diseases. Experiments were included only where previous studies had shown that the applications of related animal research had confirmed the hypotheses of the researchers, and where the experiments had achieved publication in biomedical journals.
Clinical utility of experiments expected to lead to medical advances
For 17 experiments meeting these inclusion criteria, citations were analysed for at least 12 years. Citation frequencies and types of citing papers were recorded: whether reviews, or animal-based, in vitro or clinical studies. 1,183 citations were evident; however, only 8.2% of all citations (97) were in clinical publications, and of these, only 0.3% of all citations (four publications) demonstrated a direct correlation between the results of animal experiments and human outcomes. However, even in these four cases the hypotheses that had been verified successfully in the animal experiment failed in every respect when applied to humans. None of these 17 experiments led to any new therapies or had any beneficial clinical impact during the period examined.
Accordingly, Lindl and colleagues called for serious, rather than cursory, evaluations of the likely benefits of animal experiments by animal ethics committees and related authorities, and for a reversal of the current paradigm in which animal experiments are routinely approved. Instead of approving experiments because of the possibility that benefits may accrue, Lindl and colleagues suggested that where significant doubt exists, laboratory animals should receive the benefit of that doubt, and that such experiments should not, in fact, be approved.
Clinical utility of highly cited animal experiments
Hackam and Redelmeier (2006) also utilised a citation analysis, although without geographical limitation. Based on the assumption that findings from highly cited animal experiments would be most likely to be subsequently tested in clinical trials, they searched for experiments with more than 500 citations published in the seven leading scientific journals when ranked by citation impact factor.
Of 76 animal studies located with a median citation count of 889 (range: 639-2,233), only 36.8% (28/76) were replicated in randomised human trials. 18.4% (14/76) were contradicted by randomised trials, and 44.7% (34/76) had not translated to clinical trials. Ultimately, only 10.5% (8/76) of these medical interventions were subsequently approved for use in patients. And even in these cases human benefit cannot be assumed, because adverse reactions to approved interventions are sufficiently common that they are the 4 th -6 th reading cause of death (based on a 95% confidence interval) in US Hospitals (Lazarou and Pomeranz, 1998) . The low rate of translation to clinical trials of even these highly cited animal experiments occurred despite 1992 being the median publication year, allowing a median of 14 years for potential translation. For studies that did translate to clinical trials, the median time for translation was seven years (range 1-15). Frequency of translation was unaffected by laboratory animal species, type of disease or therapy under examination, journal, year of publication, methodological quality, and even, surprisingly, citation rate. However, animal studies incorporating dose-response gradients were more likely to be translated to clinical trials (OR 3.3; 95% CI 1.1-10.1).
Although the rate of translation of these animal studies to clinical trials was low, as Hackam and Redelmeier stated it is nevertheless higher than that of most published animal experiments, which are considerably less likely to be translated than these highly cited animal studies published in leading journals. Furthermore, the selective focusing on positive animal data while ignoring negative results (optimism bias) is one of several cited factors that may increase the likelihood of translation beyond that scientifically merited. As Hackam (2007) stated, rigorous meta-analysis of all relevant animal experimental data would probably significantly decrease the translation rate to clinical trials.
Additionally, only 48.7% (37/76) of these highly cited animal studies were of good methodological quality. Despite the publication of these highly-cited animal studies in leading scientific journals, few included random allocation of animals, adjustment for multiple hypothesis testing, or blinded assessment of outcomes. Accordingly, Hackam and Redelmeier cautioned patients and physicians about extrapolating the findings of even highly cited animal research to the care of human disease.
Clinical utility of chimpanzee experiments
Chimpanzees are the species most closely related to humans, and consequently, most likely to be predictive of human outcomes when used in biomedical research. Hence, in 2005 I conducted a citation analysis examining the human clinical utility of chimpanzee experiments (Knight, 2007b) .
I searched three major biomedical bibliographic databases, locating 749 papers published between 1995 and 2004 describing experiments on captive chimpanzees or their tissues. Although published in the international scientific literature, the vast majority of these experiments were conducted within the US (Conlee et al., 2004) . To obtain 95% confidence intervals with an accuracy of at least plus or minus 10% when estimating the proportion of chimpanzee studies subsequently cited by other published papers, a subset of at least 86 chimpanzee studies was required (Morris, n.d.; Guenther, 1973; Green, 1982) .
Of 95 published chimpanzee experiments randomly selected, 49.5% (47/95) were not cited by any subsequent papers, demonstrating minimal contributions towards the advancement of biomedical knowledge generally. This is of particular concern because research of lesser value is not published; hence it appears that the majority of chimpanzee research generates data of questionable value, which makes little obvious contribution towards the advancement of biomedical knowledge.
35.8% (34/95) of 95 published chimpanzee experiments were cited by 116 papers that clearly did not describe well developed methods for combating human diseases. Only 14.7% (14/95) were cited by 27 papers that abstracts indicated described well developed methods for combating human diseases. However, detailed examination of these medical papers revealed that in vitro studies, human clinical and epidemiological studies, molecular assays and methods, and genomic studies, contributed most to their development. 63.0% (17/27) were wide-ranging reviews of 26-300 (median 104) references, to which the cited chimpanzee study made a very small contribution. Duplication of human outcomes, inconsistency with other human or primate data, and other causes resulted in the absence of any chimpanzee study able to demonstrate an essential contribution, or, in most cases, a significant contribution of any kind, towards the development of the medical method described.
Despite the low utility of chimpanzee experiments in advancing human health indicated by these results, it remains true that chimpanzees are the species most closely related to human beings. Hence it is highly likely that other laboratory species are even less efficacious when used as experimental models of humans in biomedical research and toxicity testing.
Causes for the poor human utility of animal models
Biomedical research
Chimpanzees are our closest living relatives, and consequently might be expected to have the greatest likelihood among laboratory species of accurately predicting human outcomes during biomedical research. However, despite great similarities between the structural regions of chimpanzee and human DNA, important differences between the regulatory regions exert an "avalanche" effect upon large numbers of structural genes (Bailey, 2005) . Despite nucleotide difference between chimpanzees and humans of only 1-2%, the results are differences of around 20% in protein expression (Glazko et al., 2005) , resulting in marked phenotypic differences between the species. These differences manifest in altered susceptibility to, aetiology and progression of diseases; differing absorption, tissue distribution, metabolism, and excretion of chemotherapeutic agents; and differences in the toxicity and efficacy of pharmaceuticals (Bailey, 2005; Knight, 2007b) . Such effects appear to be responsible for the demonstrated inability of most chimpanzee research to contribute substantially to the development of methods efficacious in combating human diseases (Knight, 2007b) .
Other laboratory animal species are even less similar to humans, both genetically and phenotypically, and are therefore less likely to accurately model the progression of human diseases or the responses to putative chemotherapeutic agents or toxins.
Toxicity testing
Rodents are by far the most common laboratory animal species used in toxicity studies. Several factors contribute to the demonstrated inability of rodent bioassays to reliably predict human toxicity. The stresses incurred during handling, restraint, other routine laboratory procedures, and particularly, the stressful routes of dose administration common to toxicity tests, alter immune status and disease predisposition in ways which are difficult to accurately predict, distorting disease progression and responses to putative toxic and chemotherapeutic agents (Balcombe et al., 2004; Knight et al., 2006) .
Additionally, animals have a broad range of physiological defences against general toxic insults, such as epithelial shedding and inducible enzymes, which commonly prove effective at environmentally relevant doses, but which may be overwhelmed at the high doses common to toxicity assays (Gold et al., 1998) . Carcinogenicity assays also utilise chronic dosing. These may result in insufficient rest intervals between doses for the effective operation of DNA and tissue repair mechanisms, which, as with the unnatural elevation of cell division rates during ad libitum feeding studies, may predispose to mutagenesis and carcinogenesis. Lower doses, greater intervals between exposures, intermittent feeding, or shorter total periods of exposure, which may represent a more realistic model of environmental exposures for most potential toxins, might not result in toxic changes at all (Knight et al., 2006) . Finally, differences in rates of absorption and transport mechanisms between test routes of administration and other important human routes of exposure, and the considerable variability of organ systems in response to toxic insults, between and within species, strains and genders, render attempts to accurately extrapolate human hazards from animal toxicity data difficult if not impossible (Knight et al., 2006) .
Methodological quality
At least 11 systematic reviews (Horn et al., 2001; Lucas et al., 2002; Roberts et al., 2002 and Mapstone et al., 2003 (who de- scribed the same review); Lee et al., 2003; Macleod et al., 2005a; Macleod et al., 2005b; van der Worp et al., 2005; Wilmot et al., 2005a; Willmot et al., 2005b; Hackam and Redelmeier, 2006; Perel et al., 2007) demonstrated the poor methodological quality of many of the animal experiments examined, and no systematic reviews demonstrated good methodological quality of a majority of them.
Common deficiencies included lack of sample size calculations, sufficient sample sizes, appropriate animal models (particularly, aged animals or those with comorbidities likely with certain diseases), randomised treatment allocation, blinded drug administration, blinded induction of injury, blinded outcome assessment, and conflict of interest statements. Some studies also used anaesthetics that may have altered experimental outcomes, and substantial variation was evident in the parameters assessed.
Raising standards: evidence-based medicine
Evidence-based medicine (EBM) bases clinical decisions on methodologicallysound, prospective, randomised, blinded, controlled clinical trials, and the gold standard for EBM is large prospective epidemiological studies, or meta-analyses of randomised, blinded, controlled clinical trials (Evidence-Based Medicine Working Group, 1992) . The implementation to animal experiments of EBM standards applied to human clinical trials would make results more robust and broadly applicable (Watters et al., 1999; Moher et al., 2001; Arlt and Heuwieser, 2005; Schulz, 2005; Perel et al., 2007) .
Mechanisms would be needed to ensure compliance with such standards, however. Compliance could, for example, be made prerequisite for research funding, ethics committee approval and publication of results. These measures would require the education and cooperation of funding agencies, ethics committees and journals.
Fundamental constraints on the human utility of animal models
Strategies designed to increase full and impartial examination of existing data before conducting animal studies, to decrease variation in experimental environments and protocols and to improve their methodological quality, would minimise consumption of animal, financial and other resources within experiments of questionable merit and quality, and would increase the potential human utility of animal data. However, while these problems might be minimised with concerted effort, given their widespread nature, the poor human clinical or toxicological utility of many animal experiments is unlikely to result solely from such factors alone. As stated by Perel et al. (2007) , the failure of animal models to adequately represent human disease may be another fundamental cause, which, in contrast, could be technically and theoretically impossible to overcome.
Genetic modification of animal models through the addition of foreign genes (transgenic animals) or inactivation or deletion of genes (knockout animals) is being attempted to make them more closely model humans. However, as well as being technically difficult very to achieve, such modification may not allow clear conclusions due to factors reflecting the intrinsic complexity of living organisms, e.g., the variable redundancy of some metabolic pathways between species (Houdebine, 2007) . Furthermore, the animal welfare burdens incurred during the creation and utilisation of GM animals are particularly high (Sauer et al., 2006) .
Implications for scientific validation of experimental models
Non-animal models are generally required to pass formal scientific validation prior to regulatory acceptance. In contrast, animal models are simply assumed to be predictive of human outcomes. These 27 systematic reviews of the human utility of animal experiments demonstrate the invalidity of such assumptions, even for animal models in use for long periods.
The consistent application of formal validation studies to all test models is clearly warranted, regardless of their animal, non-animal, historical, contemporary or possible future status, with appropriate consideration also given to animal welfare, ethical, legal, economic and any other relevant factors. Likely benefits would include greater selection of models truly predictive for human outcomes, increased safety of people exposed to chemicals that have passed toxicity tests, increased efficiency during the development of human pharmaceuticals and other therapeutic interventions, and decreased wastage of animal, personnel and financial resources.
Conclusions
The historical and contemporary paradigm that animal models are generally reasonably predictive of human outcomes provides the basis for their continuing widespread use in toxicity testing and biomedical research aimed at developing cures for human diseases. However, their use persists for historical and cultural reasons, rather than because they have been demonstrated to be scientifically valid. For example, many regulatory officials "feel more comfortable" with animal data (O'Connor, 1997), and some even believe animal tests are inherently valid, simply because they are conducted in animals (Balls, 2004) .
However, most existing systematic reviews have demonstrated that animal experiments are insufficiently predictive of human outcomes to provide substantial benefits during the development of human clinical interventions, or in deriving human toxicity assessments. Of 20 reviews examining clinical utility, authors concluded that animal models were significantly useful in contributing to the development of clinical interventions or substantially consistent with clinical outcomes in only two cases, one of which was contentious.
Seven additional reviews also failed to clearly demonstrate utility in predicting human toxicological outcomes such as carcinogenicity and teratogenicity. Consequently, animal data may not generally be assumed to be substantially useful for these purposes. The poor human clinical and toxicological utility of most animal models for which data exists, in conjunction with their generally substantial animal welfare and economic costs, justify a ban on animal models lacking scientific data clearly establishing their human predictivity or utility.
